2015 Kompletní literatura Kazuistiky

ACTA MEDICINAE 11/2015 Kompletní literatura Kazuistiky 2

Srdeční selhání jako primomanifestace arteriální hypertenze

2

Občas jedna tableta stačí…

2

Efektivní management syndromu demence – kombinovaná farmakoterapie a psychosociální intervence

3

Pohybová léčba jako součást komplexní léčby u ankylozující spondylitidy

3

Využití golimumabu v terapii revmatoidní artritidy a ankylozující spondylitidy

4

Tocilizumab v léčbě revmatoidní artritidy

5

Efekt belimumabu u pacientky s kombinací systémového lupusu erythematodes a myasthenia gravis po osmnácti měsících terapie

5

Léčba roztroušené sklerózy glatiramer acetátem (Copaxone inj.) v mladém věku

5

Léčba melanomu kombinací přípravků Tafinlar a Mekinist

5

Pacient léčený kombinací dabrafenibu a trametinibu

6

Dabrafenib a trametinib v léčbě pokročilého maligního melanomu

6

Abstinenční syndrom při léčbě preparátem Targin u pacienta s pokročilým nádorem pankreatu

6

Plicní rehabilitace – nedílná součást komplexní léčby nemocných s idiopatickou plicní fibrózou

6

Morbus Pompe – základní charakteristika

MUDr. Pavel Lang Oddělení všeobecné interny, Krajská nemocnice Liberec, a. s. MUDr. Jaroslav Brotánek Interní oddělení Thomayerovy nemocnice, Praha

doc. MUDr. Iva Holmerová, Ph.D. UK FHS CELLO a Gerontologické centrum, Praha MUDr. Michaela Baumanová Gerontologické centrum, Praha

PhDr. Andrea Levitová, Ph.D. Revmatologický ústav, Praha, a Fakulta tělesné výchovy a sportu UK, Praha MUDr. Hana Ciferská, Ph.D. | MUDr. Monika Urbanová | MUDr. Radka Svobodová Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

MUDr. Andrea Pavelková Revmatologický ústav, Praha MUDr. Tomáš Soukup, Ph.D. UK Praha, II. interní gastroenterologická klinika LF a FN, Hradec Králové Mgr. Martin Doseděl, Ph.D. UK Praha, Katedra sociální a klinické farmacie Farmaceutické fakulty, Hradec Králové MUDr. Jindra Brtková UK Praha, Radiologická klinika LF a FN, Hradec Králové MUDr. Drahomíra Baštecká UK Praha, II. interní gastroenterologická klinika LF a FN, Hradec Králové RNDr. Jana Nekvindová, Ph.D. Ústav klinické biochemie a diagnostiky UK Praha, LF a FN, Hradec Králové doc. PharmDr. Petr Pávek, Ph.D. UK Praha, Katedra farmakologie a toxikologie Farmaceutické fakulty, Hradec Králové doc. MUDr. Petr Bradna, CSc. UK Praha, II. interní gastroenterologická klinika LF a FN, Hradec Králové

MUDr. Zuzana Potyšová Klinika nefrologie VFN a 1. LF UK

doc. MUDr. Radomír Taláb, CSc. Neurologie – RS centrum, s. r. o., Hradec Králové MUDr. Marika Talábová Neurologická klinika FN a LF UK, Hradec Králové

MUDr. Ivana Krajsová Dermatovenerologická klinika VFN a 1. LF UK, Praha MUDr. Ondřej Kodet Dermatovenerologická klinika VFN a 1. LF UK, Anatomický ústav a 2. LF UK, Praha MUDr. Alexandr Poprach, Ph.D. | MUDr. Radek Lakomý, Ph.D. Klinika komplexní onkologické péče, MOÚ a LF MU, Brno MUDr. Radek Lakomý, Ph.D. | MUDr. Alexandr Poprach, Ph.D. Klinika komplexní onkologické péče, MOÚ a LF MU, Brno MUDr. Ondřej Sláma, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno Mgr. Kateřina Neumannová, Ph.D. Katedra fyzioterapie, Fakulta tělesné kultury UP, Olomouc MUDr. Vladimíra Lošťáková, Ph.D. Klinika plicních nemocí a tuberkulózy, LF a FN, Olomouc MUDr. Věra Malinová Stacionář pro léčbu střádavých onemocnění, Klinika dětského a dorostového lékařství, VFN a 1. LF UK, Praha

Srdeční selhání jako primomanifestace arteriální hypertenze MUDr. Pavel Lang Oddělení všeobecné interny, Krajská nemocnice Liberec, a. s. 1 Ezzati, M., et al.: Selected major risk factors and global and regional burden of disease. Lancet, 2002, 360, s. 1347–1360. 2 Cífková, R. – Bruthans, J. – Adámková, V.: Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006–2009. Studie Czech post-MONICA. Cor Vasa, 2011, 53, s. 4–5. 3 Moser, M. – Herbert, P. R.: Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol, 1996, 27, s. 1214–1218. 4 Souček, M.: Celková mortalita a antihypertenzní léčba. Remedia, 2012, 22, s. 136–140. 5 Costanzo, P. J.: Calcium channel blockers and cardiovascular

6

7 8 9

outcomes: a meta-analysis of 175,634 patients. Hypertens, 2009, 27, s. 1136–1151, doi: 10.1097/HJH.0b013e3283281254. Bramlage, P., et al.: A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patiens. J Clin Hypertens, 2010, 12, s. 666. Bangalore et al.: Resistant hypertension. J Clin Hypertens, 2006, 8, dopl. A, s. 157 (poster). Widimský, J. – Píša, Z.: Léčba hypertenze. Metodický list – nová verze 24. 10. 1989. Prakt Lék,1990, 70, s. 466–471. ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, doi:10.1093/eurheartj/eht151.

10 Pall, D.: Triple combination therapy in hypertension: The antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig, 2014, 34, s. 701–708. 11 Tóth, K.: for the PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs, 2014, 14, s. 137–145 (Erratum in Am J Cardiovasc Drugs, 2014, 14, s. 239).

Občas jedna tableta stačí… MUDr. Jaroslav Brotánek Interní oddělení Thomayerovy nemocnice, Praha 1 Vrablík, M. – Chmelík, Z. – Lánská, V.: Kdy a jak určovat kardiovaskulární riziko? Lépe dříve nežli později… Acta medicinae, 2015, 3, s. 41–45. 2 Filipovský, J. – Widimský, J. jr. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. Vnitř Lék, 2012, 10, s. 785–801. 3 Wald, D. S. – Law, M. – Morfia, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med, 2009, 122, s. 290–300. 4 Bangalore, S. – Kamalakkannan, G. – Parkar, S., et al.: Fixed-dose combinations improve medication compliance : a meta-analysis. Am J Med, 2007, 120, s. 713–719. 5 Dahlöf, B. – Sever, P. S. – Poulter, N. R., et al. for the ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian

6

7 8 9

Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 2005, 366, s. 895–906. Williams, B. – Lacy, P. S. – Thom, S. M., et al.: Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Diferential impact of blood pressure—lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 2006, 113, s. 1213–1225. Vrablík, M.: Volba kombinační léčby hypertenze a riziko metabolických komplikací. Farmakoterapie, reprint, 2012, 2, s. 7–8. Linhart, A.: Fixní kombinace inhibitorů ACE s blokátory kalciových kanálů. Farmakoterapie, reprint, 2013, 3, s. 12–14. Jamerson, K. – Weber, M. A. – Bakris, G. L., et al. for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med, 2008,

359, s. 2417–2428. 10 DiNicolantonio, J. J. – Lavie, C. D. – O‘Keefe, J. D.: Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. Postgraduate Medicine, 2013, 125, s. 154–168. 11 Ceconi, C. – Fox, K. M. – Remme, W. J., et al.: ACE inhibition with perindopril and endothelial fiction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res, 2007, 73, s. 237–246. 12 Tumanan-Mendoza, B. A. – Dans, A. L. – Villacin, L. L., et al.: Dechal lenge and rechallenge method showed different incidences of cough among four ACE-Is. J Clinic Epidem, 2007, 60, s. 805–808. 13 Lepší, P.: Současné postavení amlodipinu v léčbě systémové hypertenze. Acta medicinae, 2012, 1, s. 5–6. 14 Špác, J.: Kombinační léčba hypertenze. Acta medicinae, 2012, 1, s. 19–20. 15 Kalra, S. – Kalra, B. – Agrawal, N.: Combination therapy in hypertension: An update. Diabetol Metab Syndr, 2010, 2, s. 44.

Efektivní management syndromu demence – kombinovaná farmakoterapie a psychosociální intervence doc. MUDr. Iva Holmerová, Ph.D. UK FHS CELLO a Gerontologické centrum, Praha MUDr. Michaela Baumanová Gerontologické centrum, Praha 1 Gove, D. – Georges, J., eds.: Dementia in Europe – Yearbook 2008 with a focus on social support, socio-economic cost, psycho-social interventions and prevention. Lucembursko, Alzheimer Europe, 2009. 2 Mátl, O. – Holmerová, I. – Mátlová, M.: Zpráva o stavu demence 2014. Praha, Česká alzheimerovská společnost, 2014. 3 World Alzheimer’s Report 2015. Londýn, Alzheimer’s Disease Interna tional, 2015. 4 Burcin, B. – Kučera, T.: Prognóza populačního vývoje ČR na období 2008–2070. Praha, Rada vláda pro seniory a stárnutí populace, 2010. 5 Wimo, A. – Linus, J.: The worldwide economic impact of dementia. Alzheimer’s & Dementia, 2013, 9, s. 1–11. 6 Wimo, A. – Winblad, B. – Joenson, L.: The worldwide societal costs of dementia: Estimates for 2009. Alzheimer’s & Dementia, 2010, 6, s. 98–103. 7 Alzheimer Europe 2013 yearbook with a focus on national policies

relating to the care and support of people with dementia and their carers, as well as the prevalence of dementia including the Alzheimer Europe Annual Report 2012. Lucembursko, Alzheimer Europe, 2013. 8 Jarolímová, E. – Gramppová-Janečková, K. – Holmerová, I.: Rodiny pečující o seniora s demencí, pečovatelská zátěž a psychosociální intervence. In: Štěpánková, H. – Hoschl, C. – Vidovićová, L., ed.: Gerontologie – současné otázky z pohledu biomedicíny a společenských věd. Praha, Karolinum, 2014, s. 103–116. 9 Jarolímová, E. – Nováková, H.: Význam podpůrné (svépomocné) skupiny pro rodiny pečující o seniora se syndromem demence. Geriatire a gerontologe, 2013, 2, s. 151–153. 10 Holmerová, I. – Pešková, M.: Pečující a jejich podpora. In: Rusina, R. – Matěj, R., eds.: Neurodegenerativní onemocnění. Praha, Mladá fronta, 2014, s. 313–317. 11 Vyhnálek, M. – Bartoš, A. – Dostál, V. – Franková, V. – Holmerová,

I., et al.: Diagnostikujeme a léčíme demence správně a včas Výsledky průzkumu ve světle nových doporučení. Neurol prax, 2011, 12, s. 342–346. 12 Vasse, E. – Vernooij-Dassen, M. – Cantegreil, I. – Franco, M. – Dorenlot, P. – Woods, B., et al.: Guidelines for psychosocial interventions in dementia care: a European survey and comparison. Int J Geriatr Psychiatry, 2012, 27, s. 40–48. 13 Van Mierlo, L. D. – Meiland, F. J. – Van der Roest, H. G. – Droes, R. M.: Personalised caregiver support: effectiveness of psychosocial interventions in subgroups of caregivers of people with dementia. Int J Geriatr Psychiatry. 2012, 27, s. 1–14. 14 Holmerová, I.: Psychosociální intervence. In: Rusina, R. – Matěj, R., ed.: Neurodegenerativní onemocnění. Praha, Mladá fronta, 2014, s. 288–293.

ACTA MEDICINAE 11/2015 KAZUISTIKY Kompletní literatura

Pohybová léčba jako součást komplexní léčby u ankylozující spondylitidy PhDr. Andrea Levitová, Ph.D. Revmatologický ústav, Praha, a Fakulta tělesné výchovy a sportu UK, Praha 1 Sieper, J. – Rudwaleit, M. – Khan, M. A., et al.: Concepts and epidemiology of spondylarthritis. Best Pract Res Clin Rheumatol, 2006, 20, s. 401–417. 2 Vander Cruysen, B. – Ribbens, C. – Boonen, A., et al.: The epidemiology of ankylosing spondylitis and commencement of anti TNF therapy in daily rheumatology practise. Ann Rheum Dis, 2007, 66, s. 1072–1077. 3 Forejtová, Š.: Diagnostika a léčba spondylartritid. Medicína pro praxi, 2009, 6, s. 30–33. 4 Braun, J. – Sieper, J.: Ankylosing spondylitis. Lancet, 2007, 369, s. 1379–1390. 5 Braun, J. – Brandt, J. – Listing, J., et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet, 2002, 359, s. 1187–1193. 6 Rudwaleit, M. – van der Heijde, D. – Landewe, R., et al.: The development of Assessment of Spondyloarthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis, 2009, 68, s. 777–783. 7 Forejtová, Š. – Mann, H. – Štolfa, J. – Vedral, K. – Fenclová, I. – Nemethová, D. – Pavelka, K.: Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. Clin Rheumatol, 2008, 27, s. 1005–1013. 8 Pavelka, K.: Kohortová studie u ankylozující spondylitidy v regionu střední Evropy: aktivita nemoci, způsoby léčby a možnosti uplatnění biologické léčby. Česká Revmatologie, 2008, 2, s. 64–69. 9 van der Linden, S. – Valkenburg, H. A. – Cats, A.: Evaluation of

diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York Criteria. Arthritis Rheum, 1984, 27, s. 361–368. 10 Sieper, J. – Rudwaleit, M.: Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis, 2005, 64, s. 659–663. 11 Forejtová, Š. – Mann, H. – Štolfa, J. et al.: Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic. Clin Rheumatol, 2008, 27, s. 1005–1013. 12 Rudwaleit, M. – Khan, M. A. – Sieper, J.: The challenge of diagnosis and classification in early ankylosing spondylitis. Do we need new criteria? Arthritis Rheum, 2005, 52, s. 1000–1008. 13 Pavelka, K.: Časná diagnostika ankylozující spondylitidy. Vnitř Lék, 2006, 52, s. 726–729. 14 Rudwaleit, M. – van der Heijde, D. – Khan, M. A., et al.: How to diagnose axial spondyloarthritis early. Ann Rheum Dis, 2004, 63, s. 535–543. 15 Sieper, J. – van der Heijde, D. – Landewe, R., et al.: New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis, 2009, 68, s. 784–788. 16 Braun, J. – van den Berg, R. – Baraliakos, X., et al.: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis, 2011, 70, s. 896–904. 17 Wanders, A. – Heijde, D. – Landewe, R., et al.: Nonsteroidal anti inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum,

2005, 52, s. 1756–1765. 18 Šenolt, L.: Současný pohled na diagnostiku a léčbu. Interní medicína pro praxi, 2011, 13, s. 374–377. 19 Pavelka, K.: Doporučení České revmatologické společnosti pro léčbu ankylozující spondylitidy. Čes Revmatol, 2012, 20, s. 4–11. 20 Dagfinrud, H. – Hagen, K. B. – Kvien, T. K.: Physiotherapy interven tions for ankylosing spondylitis (Cochrane Review). The Cochrane Database of Systematic Reviews, 2004, 4, CD002822. 21 Dagfinrud, H. – Kvien, T. K. – Hagen, K. B.: Physiotherapy interven tions for ankylosing spondylitis. Cochrane Database Syst Rev, 2008, 18, CD002822. 22 Dagfinrud, H. – Halvorsen, S. – Vøllestad, N. K., et al.: Exercise programs in trials for patients with ankylosing spondylitis: Do they really have the potential for effectiveness? Arthritis Care & Research, 2011, 63, s. 597–603. 23 O’Dwyer, T. – O’Shea, F. – Wilson, F.: Exercise therapy for spondyloarthritis: a systematic review. Rheumatol Int, 2014, 34, s. 887–902. 24 Giannoti, E., et al.: Effects of physical therapy for the management of patients with ankylosing spondylitis in the biological era. Clin Rheumatol, 2014, 33, s. 1217–1230. 25 Hulejová, H. – Levitová, A. – Kuklová, M. – Štochl, J. – Haluzík, M. – Pavelka K. – Vencovský, J. – Šenolt, L.: No effect of psychiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. Clinical Rheumatology, 2012, 31, s. 67–71.

Využití golimumabu v terapii revmatoidní artritidy a ankylozující spondylitidy MUDr. Hana Ciferská, Ph.D. | MUDr. Monika Urbanová | MUDr. Radka Svobodová Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha 1 Mazumdar, S. – Greenwald, D.: Golimumab. MAbs, 2009, 1, s. 422–431. 2 Choy, E. H. – Kavanaugh, A. F. – Jones, S. A.: The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol, 2013, 9, s. 154–163. 3 Aletaha, D. – Neogi, T. – Silman, A. J., et al.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis, 2010, 69, s. 1580–1588. 4 Goldman, K. – Gertel, S. – Amital, H.: Anti-citrullinated peptide antibodies is more than an accurate tool for diagnosis of rheumatoid arthritis. Isr Med Assoc J, 2013, 15, s. 516–519. 5 Scott, D. L. – Wolfe, F. – Huizinga, T. W.: Rheumatoid arthritis. Lancet, 2010, 376, s. 1094–1108. 6 van der Linden, S. – Valkenburg, H. A. – Cats, A.: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York Criteria. Arthritis Rheum, 1984, 27, s. 361–368. 7 Rudwaleit, M. – van der Heide, D. – Landewe, R., et al.: Development of ASAS for axial spondylarthritis, validation of final section.

Ann Rheum Dis, 2009, 68, s. 777–783. 8 Emery, P. – Fleischmann, R. – van der Neujde, D., et al.: Golimumab and radiographic progression in rheumatoid arthritis: results of GO-BEFORE and GO-FORWARD studies. Arthritis Rheum, 2009, 10 (dopl.), s. 640. 9 European Medicines Agency, Simponi (golimumab) EU Souhrnné informace o přípravku, dostupné z: http://www.ema.europa.eu/ docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000992/WC500052368.pdf, vyhledáno 18. 8. 2014. 10 Emery, P. – Fleischmann, R. M. – Strusberg, I., et al.: Efficacy and safety of subcutaneous golimumab in methotrexate-naïve patients with rheumatoid arthritis: 5-year results of the GO-BEFORE trial. Arthritis Care Res (Hoboken). 2015, 16, doi: 10.1002/acr.22759 (Epub před tiskem). 11 Keystone, E. C. – Genovese, M. C. – Hall, S., et al.: Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol, 2013, 40, s. 1097–1103. 12 Smolen, J. S. – Kay, J. – Landewé, R. B., et al.: Golimumab in patients

with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis, 2012, 71, s. 1671–1679. 13 Alfonso, A. – González, C. M. – Balouna, J., et al.: Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain. Reumatol Clin, 2015, 11, s. 144–150. 14 Takeuchi, T. – Harigai, M. – Tahala, Y., et al.: GO-MONO study group. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. Ann Rheum Dis, 2013, 72, s. 1488–1495. 15 Braun, J. – Baraliakos, X. – Hermann, K. G., et al.: The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis, 2014, 73, s. 1107–1113.


Tocilizumab v léčbě revmatoidní artritidy MUDr. Andrea Pavelková Revmatologický ústav, Praha 1 Smolen, J. S. – Landewe, R. – Breedveld, F. C., et al.: EULAR recom mendations for the management of rheumatoid arthritis with syntethic and biological dinase-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis, 2014, 73, s. 492–509. 2 Ohsugi, Y. – Kishimoto, T.: The recombinant humanized anti IL-6 receptor antibody tocilizumab, an innovate drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther, 2008, 8, s. 669–681. 3 Mann, H.: Tocilizumab v léčbě revmatoidní artritidy. Farmakoterapie, 2008, 6, s. 574–579. 4 Smolen, J. S. – Beauileu, A. – Rubbert-Roth, A., et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patiens with rheumatoid arthritis: a doubble-blind, placebo-controlled, randomised trial. Lancet, 2008, 371, s. 987–997. 5 Genovese, M. C. – McKay, J. D. – Nasonov, E. L., et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum, 2008, 58, s. 2968–2980.

6 Emery, P. – Keystone, E. – Tony, H. P., et al.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patiens with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: result from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis, 2008, 67, s. 1516–1523. 7 Jones, G. – Gu, J. R. – Lowenstein, M., et al.: Tocilizumab monotherapy is superior to methotrexate monotherapy in reducing disease activity in patients with rheumatoid arthritis. Ann Rheum Dis, 2008, 67, s. 89. 8 Kremer, J. M. – Fleischmann, R. M. – Halland, A. M.: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate. ACR, 2008, abstrakt L14. 9 Kivitz, A. – Olech, E. – Borofsky, M., et al.: Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken), 2014, 66, s. 1653–1661. 10 Ogata, A. – Amano, K. – Dobashi, H., et al.: Longterm safety and efficacy of subcutaneous tocilizumab monotherapy: Results from the 2-year open-label extension of the MUSASHI study. J Rheumatol, 2015,

42, s. 799–809. 11 Burmester, G. R. – Rubbert-Roth, A. – Cantagrel, A., et al.: A randomised, doubble-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis, 2014, 73, s. 69–74. 12 Slíva, J.: Využití tocilizumabu v subkutánní formě k léčbě revmatoidní artritidy. Farmakoterapie, 2015, 11, s. 354–355. 13 Smolen, J. S. – Beaulieu, A. D. – Dikranian, A., et al.: Safety of tocilizumab on patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. Arthritis Rheum, 2008, 58, s. S784. 14 Hirao, M. – Hashimoto, J. – Tsuboi, H., et al.: Laboratory and fibrile features after joint surgery in rheumatoid arthritis patients treated with tocilizumab. Ann Rheum Dis, doi:10.1136/ard.2008.090068. 15 Genovese, M. C. – Smolen, J. S. – Emery, P., et al.: Lipid and inflammatory biomarker profiles in patients receiving tocilizumab for rheumatoid arthritis: analysis of five phase 3 clinical trials. Arthritis Rheum, 2008, 58, s. S531–S532.

MUDr. Tomáš Soukup, Ph.D. UK Praha, II. interní gastroenterologická klinika LF a FN, Hradec Králové Mgr. Martin Doseděl, Ph.D. UK Praha, Katedra sociální a klinické farmacie Farmaceutické fakulty, Hradec Králové MUDr. Jindra Brtková UK Praha, Radiologická klinika LF a FN, Hradec Králové MUDr. Drahomíra Baštecká UK Praha, II. interní gastroenterologická klinika LF a FN, Hradec Králové RNDr. Jana Nekvindová, Ph.D. Ústav klinické biochemie a diagnostiky UK Praha, LF a FN, Hradec Králové doc. PharmDr. Petr Pávek, Ph.D. UK Praha, Katedra farmakologie a toxikologie Farmaceutické fakulty, Hradec Králové doc. MUDr. Petr Bradna, CSc. UK Praha, II. interní gastroenterologická klinika LF a FN, Hradec Králové 1 Hider, S. L. – Buckley, C. – Silman, A. J., et al.: Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheum, 2005, 32, s. 11–16. 2 Anderson, J. J. – Wells, G. – Verhoeven, A. C. – Felson, D. T.: Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration. Arthritis Rheum, 2000, 43, s. 22–29. 3 Fonseca, J. E. – Canhao, H. – Teixeira da, C. J., et al.: Global functional status in rheumatoid arthritis: Disease duration and patient age. Clin Rheum, 2002, 21, s. 32–34. 4 Ronnelid, J. – Wick, M. C. – Lampa, J., et al.: Longitudinal analysis of citrullinated protein/peptide antibodies (anti-cp) during 5 year follow up in early rheumatoid arthritis: Anti-cp status predicts worse disease activity and greater radiological progression. An Rheum Dis. 2005, 64, s. 1744–1749. 5 Papadopoulos, N. G. – Alamanos, Y. – Voulgari, P. V., et al.: Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheum, 2005, 23, s. 861–866. 6 Morel, J. – Combe, B.: How to predict prognosis in early rheumatoid arthritis. Best Pract Res Clin Rheumatol, 2005, 19, s. 137–146. 7 van der Helm-van Mil, A. H. – Verpoort, K. N. – Breedveld, F. C., et al.: Antibodies to citrullinated proteins and differences in clinical progres sion of rheumatoid arthritis. Arthritis Res Ther, 2005, 7, s. R949–R958. 8 van der Heijden, J. W. – Dijkmans, B. A. – Scheper, R. J., et al.: Drug insight: Resistance to methotrexate and other disease-modifying antirheumatic drugs—from bench to bedside. Nat Clin Pract Rheumatol, 2007, 3, s. 26–34. 9 Svendsen, A. J. – Kyvik, K. O. – Houen, G., et al.: On the origin of rheumatoid arthritis: The impact of environment and genes—a population based twin study. PLoS One, 2013, 8, s. e57304. 10 Ranganathan, P. – McLeod, H. L.: Methotrexate and long-term treat ment of rheumatic disease: Comment on the article by kremer. Arthritis Rheum, 2005; 52:670–1. 11 Aggarwal, P. – Naik, S. – Mishra, K. P., et al.: Correlation between methotrexate efficacy & toxicity with c677t polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate

supplementation. Indian J Med Res, 2006, 124, s. 521–526. 12 Urano, W. – Taniguchi, A. – Yamanaka, H., et al.: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treat ment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics, 2002, 12, s. 183–190. 13 Wessels, J. A. – de Vries-Bouwstra, J. K. – Heijmans, B. T., et al.: Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum, 2006, 54, s. 1087–1095. 14 Owen, S. A. – Hider, S. L. – Martin, P., et al.: Genetic polymorphisms in key methotrexate pathway genes are associated with response to treat ment in rheumatoid arthritis patients. Pharm J, 2013, 13, s. 227–234. 15 Wessels, J. A. – van der Kooij, S. M. – le Cessie, S., et al.: Pharmacogenetics Collaborative Research G. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum, 2007, 56, s. 1765–1775. 16 Picascia, A. – Grimaldi, V. – Pignalosa, O., et al.: Epigenetic control of autoimmune diseases: From bench to bedside. Clin Immunol, 2015, 157, s. 1–15. 17 Soukup, T. – Dosedel, M. – Pavek, P., et al.: The impact of c677t and a1298c mthfr polymorphisms on methotrexate therapeutic response in east bohemian region rheumatoid arthritis patients. Rheum Int, 2015, 35, s. 1149–1161. 18 Arnett, F. C. – Edworthy, S. M. – Bloch, D. A., et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31, s. 315–324. 19 van der Heijde, D. M. F. M. – van Leeuwen, M. A. – van Riel, P. L. C. M., et al.: Biannual radiographic assessments of hands and feet in a three-year prospective followup study of patients with early rheumatoid arthritis. Arthritis Rheum, 1992, 35, s. 26–34. 20 Imboden, J. B. – Stone, J. H.: Rheumatoid arthritis: The disease-diagnosis and clinical features. In: Imboden, J. B. – Hellmann, D. B. – Stone, J. H., eds.: Current rheumatology diagnosis & treatment. Mcgraw Hill Professional, 2006, s. 508. 21 Nesher, G. – Mates, M. – Zevin, S.: Effect of caffeine consumption

on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum, 2003, 48, s. 571–572. 22 Montesinos, M. C. – Yap, J. S. – Desai, A., et al.: Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum, 2000, 43, s. 656–663. 23 Fries, J. F. – Wolfe, F. – Apple, R., et al.: HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum, 2002, 46, s. 2320–2329. 24 Owen, S. A. – Lunt, M. – Bowes, J., et al.: Mthfr gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: Analysis of key polymorphisms and meta-analysis of c677t and a1298c polymorphisms. Pharm J, 2013, 13, s. 137–147. 25 Hider, S. L. – Thomson, W. – Mack, L. F., et al.: Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology (Oxford), 2008, 47, s. 1156–1159, doi: 10.1093/rheumatology/ken182, Epub 6. 6. 2008. 26 Smolen, J. S. – Landewé, R. – Breedveld, F. C., et al.: EULAR recom mendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis, 73, s. 492–509, doi: 10.1136/annrheumdis-2013-204573, Epub 25. 10. 2013. 27 Nishimoto, N. – Hashimoto, J. – Miyasaka, N., et al.: Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis, 2007, 66, s. 1162–1167. 28 Huizinga, T. W. J. – Conaghan, P. G. – Martin-Mola, E., et al.: Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis, doi 10.1136/ann rheumdis-2014-205752. www.ncbi.nlm.nih.gov/pubmed/25169728, E-pub srpen 2014.


Efekt belimumabu u pacientky s kombinací systémového lupusu erythematodes a myasthenia gravis po osmnácti měsících terapie MUDr. Zuzana Potyšová Klinika nefrologie VFN a 1. LF UK 1 Kamal, A. – Khamashta, M.: The efficacy of novel B cell biologics as the future of SLE treatment: A review. Autoimmun Rev, 2014, 13, s. 1094–1101.

2 Ciferská, H.: Belimumab v terapii systémového lupus erythematodes. Farmakoterapie, 2012, 1. 3 Potyšová, Z.: Postavení belimumabu v léčbě pacientky s kombinací

myasthenia gratis a systémového lupusu erythematodes. Acta medicinae. Speciál, 2014, s. 32–33.

Léčba roztroušené sklerózy glatiramer acetátem (Copaxone inj.) v mladém věku doc. MUDr. Radomír Taláb, CSc. Neurologie – RS centrum, s. r. o., Hradec Králové MUDr. Marika Talábová Neurologická klinika FN a LF UK, Hradec Králové 1 Chitnis, T. – Tardieu, M. – Amato, M. P., et al.: International Pediatric MS Study Group Clinical trials Summit: Meeting report. Neurology, 2013, 80, s. 1161–1168. 2 Polman, C. H. – Reingold, S. C. – Banwell, B., et al.: Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonadl Criteria. Ann Neurol, 2011, 69, s. 292–302. 3 Mikaeloff, Y. – Caridade, G. – Tardieu, M. – Suissa, S.: Hepatitis B valine and the risk of CNS inflamatory demyelination in childhood. Neurology, 2009, 72, s. 873–880. 4 Mikaeloff, Y. – Caridade, G. – Tardieu, M., et al.: KIDSEP Study group. Parental smoking at home and the risk of childhood onset multiple sclerosis in children. Brain, 2007, 130, s. 2589–2595. 5 Mowry, E. M. – Krupp, L. B. – Milazzo, M., et al.: Vitamin D status is associated with relapse rate in pediatric onset multiple sclerosis. Ann

Neurol, 2010, 5, s. 618–624. 6 Chaudhuri, A.: Why we should offer routine vitamin D supplementation in pregnancy and childhood do prevent multiple sclerosis. Med Hypotheses, 2005, 64, s. 608–618. 7 Masterman, T. – Litera, A. – Olsson, T., et al.: HLA-DR15 is associated with early age at onset in multiple sclerosis. Ann Neurol, 2000, 48, s. 211–219. 8 Dyment, D. A. – Ebers, G. C. – Sadovnick, A. D.: Genetics of multiple sclerosis. Lancet Neurol, 2004, 3, s. 104–110. 9 Correale, J. – Tenembaum, S. N.: Myelin basic protein and myelin oligodendrocyte glykoprotein T-cell repertoire in childhood and juvenilie multiple sclerosis. Mult Scler, 2006, 12, s. 412–420. 10 Pena, J. A. – Lotze, T. E.: Pediatric multiple sclerosis: current concepts and konsensus definitions. Autoimmune Dis, 2013, s. 1–12.

11 Krupp, L. B. – Tardieu, M. – Amato, M. P., et al.: International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler, 2013, 19, s. 1261–1267. 12 Yeh, E. A.: Management of children with multiple sclerosis. Paediatric Drugs, 2012,3, s. 165–177. 13 Talab, R.: Glatiramer acetát. Farmakoterapie, 2006, 3, s. 271–276. 14 Farina, C. – Weber, M. S. – Meinl, E., et al.: Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol, 2005, 4, s. 567–575. 15 Houtchens, M. K. – Kolb, C. M.: Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol, 2013, 260, s. 1202–1214.

Léčba melanomu kombinací přípravků Tafinlar a Mekinist MUDr. Ivana Krajsová Dermatovenerologická klinika VFN a 1. LF UK, Praha MUDr. Ondřej Kodet Dermatovenerologická klinika VFN a 1. LF UK, Anatomický ústav a 2. LF UK, Praha 1 Chapman, P. B. – Hauschild, A. – Robert, C., et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011, 364, s. 2507–2516. 2 Hauschild, A. – Grob, J. J. – Demidov, L. V., et al.: Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2012, 380, s. 358–365. 3 Solit, B. – Rosen, N.: Resistance to BRAF inhibition in melanomas.

N Engl J Med, 2011, 364, s. 772–774. 4 Robert, C. – Karaszewska, B. – Schachter, J., et al.: Improved over all survival in melanoma with combined dabrafenib and trametinib. N Engl J Med, 2015, 372, s. 30–39. 5 Long, G. V. – Trefzer, U. – Davies, M. A. – Kefford, R. F., et al.: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase

2 trial. Lancet, 2012, 13, s. 1087–1095. 6 Marquez-Rodas, J. – Avilez-Izquierdo, J. A. – Alvarez-Gonzales, A., et al.: Exclusion criteria versus reality: dual BRAF/MEK inhibition and radiotherapy in a patient with melanoma metastatic to the brain and ECOG 3. Tumori, 27. 8. 2015, doi: 10.5301/tj.5000408 (Epub před tiskem).

Pacient léčený kombinací dabrafenibu a trametinibu MUDr. Alexandr Poprach, Ph.D. | MUDr. Radek Lakomý, Ph.D. Klinika komplexní onkologické péče, MOÚ a LF MU, Brno 1 Bhatia, S. – Tykodisi, S. S. – Thompson, J. A.: Treatment of metastatic melanoma: An overview. Oncology (Williston Park, NY), 2009, 23, s. 488–496. 2 Schadendorf, D. – Hodi, F. S. – Robert, C., et al.: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol, 2015, 33, s. 1889–1894, doi: 10.1200/JCO.2014.56.2736, Epub 9. 2. 2015. 3 Johnson, D. B. – Peng, C. – Sosman, J. A.: Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol, 2015, 7,

s. 97–106. 4 Improta, G. – Leone, I. – Donia, M., et al.: New developments in the management of advanced melanoma—role of pembrolizumab. Onco Targets Ther, 2015, 8, s. 2535–2543. 5 Larkin, J. – Chiarion-Sileni, V. – Gonzalez, R., et al.: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med, 2015, 373, s. 23–34. 6 Long, G. V. – Stroyakovskiy, D. – Gogas, H., et al.: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl

J Med, 2014, 371, s. 1877–1888. 7 Robert, C. – Karaszewska, B. – Schachter, J., et al.: Improved over all survival in melanoma with combined dabrafenib and trametinib. N Engl J Med, 2015, 372, s. 30–39. 8 Larkin, J. – Ascierto, P. A. – Dréno, B., et al.: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med, 2014, 371, s. 1867–1876.


Dabrafenib a trametinib v léčbě pokročilého maligního melanomu MUDr. Radek Lakomý, Ph.D. | MUDr. Alexandr Poprach, Ph.D. Klinika komplexní onkologické péče, MOÚ a LF MU, Brno 1 Ramanujam, S. – Schadendorf, D. – Long, G. V.: Systemic therapies for melanoma brain metastases: which drug for whom and when? Chin Clin Oncol, 2015, 4, s. 25. 2 Long, G. V. – Menzies, A. M. – Nagrial, A. M., et al.: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol, 2011, 29, s. 1239–1946. 3 Bucheit, A. D. – Syklawer, E. – Jakob, J. A., et al.: Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer, 2013, 119, s. 3821–3829. 4 Chapma, P. B. – Hauschild, A. – Robert, C., et al.: BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011, 364, s. 2507–2516. 5 McArthur, G. A. – Chapman, P. B. – Robert, C., et al.: Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) muta tion-positive melanoma (BRIM-3): extended follow-up of a phase 3,

randomised, open-label study. Lancet Oncol, 2014, 15, s. 323–332. 6 Hauschild, A. – Grob, J. – Demidov, L., et al.: An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J Clin Oncol, 2013, 31 (dopl., abstrakt 9013). 7 Lacouture, M. E. – Duvic, M. – Hauschild, A., et al.: Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist, 2013, 18, s. 314–322. 8 Larkin, J. – Del Vecchio, M. – Ascierto, P. A., et al.: Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol, 2014, 15, s. 436–444. 9 Anforth, R. – Menzies, A. – Byth, K., et al.: Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. J Am Acad Dermatol, 2015, 72, s. 809–815. 10 Chan, M. M. – Haydu, L. E. – Menzies, A. M., et al.: The nature and

management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer, 2014, 120, s. 3142–3153. 11 Flaherty, K. T. – Infante, J. R. – Daud, A., et al.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med, 2012, 367, s. 1694–1703. 12 Long, G. V. – Stroyakovskiy, D. – Gogas, H., et al.: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med, 2014, 371, s. 1877–1888. 13 Robert, C. – Karaszewska, B. – Schachter, J., et al.: Improved over all survival in melanoma with combined dabrafenib and trametinib. N Engl J Med, 2015, 372, s. 30–39. 14 Larkin, J. – Ascierto, P. A. – Dréno, B., et al.: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med, 2014, 371, s. 1867–1876.

Abstinenční syndrom při léčbě preparátem Targin u pacienta s pokročilým nádorem pankreatu MUDr. Ondřej Sláma, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno 1 Bell, T. J. – Panchal, S. J. – Miaskowski, C., et al.: The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med, 2009, 10, s. 35–42. 2 Tuteja, A. K. – Biskupiak, J. – Stoddard, G. J., et al.: Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil, 2010, 22, s. 424–430.

3 Ahmedzai, S. H. – Leppert, W. – Janecki, M., et al.: Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer, 2014. 4 Vondrackova, D. – Leyendecker, P. – Meissner, W., et al.: Analgesic efficacy and safety of oxycodone in combination with naloxone as

prolonged release tablets in patients with moderate to severe chronic pain. J Pain, 2008, 9, s. 1144–1154. 5 Sandner-Kiesling, A. – Leyendecker, P. – Hopp, M., et al.: Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract, 2010, 64, s. 763–774.

Plicní rehabilitace – nedílná součást komplexní léčby nemocných s idiopatickou plicní fibrózou Mgr. Kateřina Neumannová, Ph.D. Katedra fyzioterapie, Fakulta tělesné kultury UP, Olomouc MUDr. Vladimíra Lošťáková, Ph.D. Klinika plicních nemocí a tuberkulózy, LF a FN, Olomouc 1 Raghu, G. – Collard, H. R. – Egan, J. J., et al.: An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Resp Crit Care Med, 2011, 183, s. 788–824. 2 Šterclová, M. – Vašáková, M.: Intersticiální plicní procesy v otázkách a odpovědích. General Practitioner/Prakticky Lekar, 2011, 91, s. 707–709. 3 Du Bois, R. M.: Strategies for treating idiopathic pulmonary fibrosis. Nature Reviews Drug Discovery, 2010, 9, s. 129–140.

4 Vašáková, M.: Novinky v léčbě idiopatické plicní fibrózy. Interní Med, 2014, 16, s. 189–191. 5 Spruit, M. A. – Singh, S. J. – Garvey, C., et al.: An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Resp Crit Care Med, 2013, 188, s. e13–e64. 6 Bolton, C. E. – Bevan-Smith, E. F. – Blakey, J. D., et al. & British Thoracic Society Standards of Care Committee: British Thoracic Society

guideline on pulmonary rehabilitation in adults. Thorax, 2013, 68, s. ii1. 7 Neumannová, K. – Zatloukal, J. – Koblížek, V.: Doporučený postup plicní rehabilitace, 2014. Dostupné z: www.pneumologie.cz. 8 Holland, A. E. – Hill, C. J. – Conron, M., et al.: Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax, 2008, 63, s. 549–554.

Morbus Pompe – základní charakteristika MUDr. Věra Malinová Stacionář pro léčbu střádavých onemocnění, Klinika dětského a dorostového lékařství, VFN a 1. LF UK, Praha 1 Kishnani, P. S. – Steiner, R. D. – Bali, D., et al.: Pompe disease diagnosis and management guideline; ACMG Work Group on Management of Pompe Disease. Genet Med, 2006, 8, s. 267–288, doi: 10.1097/01. gim.0000218152.87434.f3. PMCID: PMC3110959.

2 Regnery, C. – Kornblum, C. – Hanisch, F., et al.: 36 month observational clinical study of 38 adult Pompe disease patients under alglukosidase alfa enzyme replacement therapy. J Inherit Metab Dis, doi: 10.1007/10545-012-9451-8, publikováno online 31. 1. 2012.

3 Kishnani, P. S. – Beckemeyer, A. A. – Mendelsohn, N. J.: The new era of Pompe disease: Advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. American Journal of Medical Genetics Part C, 2012, 160C, s. 1–7.


2015 Kompletní literatura Kazuistiky

Recommend Documents